Render Target: SSR
Render Timestamp: 2024-11-17T18:30:26.662Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-09-20 06:19:03.626
Product last modified at: 2024-05-30T07:16:49.522Z
1% for the planet logo
PDP - Template Name: Growth Factors and Cytokines
PDP - Template ID: *******9ad1159

Human Interleukin-6 (hIL-6) #8904

We recommend the following alternatives

Inquiry Info. # 8904

Please see our recommended alternatives.

    Product Information

    Formulation

    With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-6. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.

    Storage

    Stable in lyophilized state at -20°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.
    Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

    Product Description

    MW (kDa) 22
    Purity >98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-6. All lots are greater than 98% pure.
    Endotoxin Less than 0.01 ng endotoxin/1 μg hIL-6.
    Activity The bioactivity of recombinant hIL-6 was determined in a TF-1 cell proliferation assay. The ED50 of each lot is between 0.2-0.7 ng/ml.
    Molecular Formula Based on amino acid sequencing, greater than 60% of recombinant hIL-6 has a Met on the amino-terminal Val30 (sequence of MVPPG) and has a calculated MW of 20,943. The remainder starts at pro 32 (sequence of PPGED) or Pro33 (sequence of PGEDS). DTT-reduced protein migrates as a 23 kDa polypeptide and non-reduced protein migrates as a 22 kDa polypeptide due to intramolecular cystines.

    Source / Purification

    Recombinant human IL-6 (hIL-6) Val30-Met212 (Accession #NM_000600) was produced in E. coli at Cell Signaling Technology.

    Background

    IL-6 is a potent inducer of the acute phase response and is produced by T cells, macrophages, fibroblasts, endothelial and other cells (1,2). IL-6 induces proliferation and differentiation and acts on B cells, T cells, thymocytes, and others. IL-6 in concert with TGFβ is important for developing Th17 responses. IL-6 binds to IL-6Rα and through this association induces gp130 homodimerization (1). gp130 homodimerization triggers the Jak/Stat cascade and the SHP2/Erk MAP kinase cascade (1,3,4). IL-6 also forms a complex with an IL-6Rα splice variant that is non-membrane associated (3).The IL-6/soluble IL-6Rα complex can then activate the gp130 signaling pathway on cells that express gp130 but not IL-6Rα (3). IL-6, through increasing expression of proangiogenic VEGF, may contribute to metastatic breast cancer (5).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.